GlassScriptPhysician profile
Henry Kaggwa
NPI 1578107959
$5,575.46
in general payments reported to CMS, 2019-2025
15 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $952 · 2022: $986 · 2023: $902 · 2024: $851 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834 · Travel and Lodging: $666 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,833.84 |
| Travel and Lodging | $666.01 |
| Education | $137.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,869.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $966.29 | 2024-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $401.28 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $302.08 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $225.52 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $199.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.97 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $129.37 | 2025 | Cobenfy |
| Lundbeck LLC | $84.35 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $77.93 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $62.21 | 2021-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $57.96 | 2024-2025 | Uzedy |
| Tempus Ai, INC | $27.94 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.83 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Kaggwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.